Search

Displaying results 7531 - 7540 of 8696 in total
  1. Drug

    Fluasterone

    go.drugbank.com/drugs/DB06250
    Experimental

    Has antiproliferative effects on HIV-1 and reduces HIV-1 replication.

  2. Drug

    ONT-093

    go.drugbank.com/drugs/DB14069
    Experimental

    ONT-093 is an orally bioavailable inhibitor of P-glycoprotein (P-gp). … In pre-clinical studies, ONT-093 could inhibit P-gp and reverse multidrug resistance at nM concentrations with no effect on paclitaxel pharmacokinetics.

    Categories: P-glycoprotein inhibitors
  3. Drug

    Rineterkib

    go.drugbank.com/drugs/DB17560
    Investigational

    Rineterkib is an inhibitor of extracellular signal-regulated kinase (ERK) being investigated in NCT04097821 (A Randomized, Open-label, Phase I/II Open Platform Study Evaluating Safety and Efficacy of Novel

  4. Drug

    Omapatrilat

    go.drugbank.com/drugs/DB00886
    Experimental

    Omapatrilat is an investigational drug that inhibits both neutral endopeptidase (NEP) and angiotensin converting enzyme (ACE).

  5. Drug

    Tovinontrine

    go.drugbank.com/drugs/DB16193
    Investigational

    Tovinontrine is an orally administered, highly selective phosphodiesterase 9 (PDE9) small molecule inhibitor.

  6. Drug

    TBX-3400

    go.drugbank.com/drugs/DB17370
    Investigational

    TBX-3400 is an investigational cell-based immunotherapy consisting of autologous peripheral blood mononuclear cells (PBMCs) treated ex vivo with TBX-4000, which is a recombinant TAT-MYC fusion protein.

  7. Drug

    Huperzine B

    go.drugbank.com/drugs/DB03348
    Experimental

    Huperzine B is a novel acetylcholinesterase inhibitor.

  8. Drug

    Calcium silicate

    go.drugbank.com/drugs/DB13829
    Investigational

    Categories: Drugs for Acid Related Disorders
  9. Drug

    Aconiazide

    go.drugbank.com/drugs/DB17731
    Experimental

    Categories: Drugs for Treatment of Tuberculosis
  10. Drug

    Deutarserine

    go.drugbank.com/drugs/DB19057
    Investigational

    Deutarserine is under investigation in clinical trial NCT04158687 (A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-692 as an Adjunctive Treatment in Adults With Schizophrenia).